Status:
RECRUITING
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
Lead Sponsor:
Timothy Mullett
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-120 years
Phase:
NA
Brief Summary
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer ...
Eligibility Criteria
Inclusion
- Clinically suspected or histologically confirmed stage IIb-IV NSCLC who are planning to undergo treatment
- No prior systemic therapies for NSCLC, with the exception of adjuvant therapy for early stage NSCLC. Prior surgery and/or radiation is allowed.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.
- Pregnancy
Key Trial Info
Start Date :
April 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2036
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05254795
Start Date
April 13 2022
End Date
December 1 2036
Last Update
August 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40506